CN104415027A - Application of allicin in adjusting animal intestinal flora - Google Patents
Application of allicin in adjusting animal intestinal flora Download PDFInfo
- Publication number
- CN104415027A CN104415027A CN201310390605.1A CN201310390605A CN104415027A CN 104415027 A CN104415027 A CN 104415027A CN 201310390605 A CN201310390605 A CN 201310390605A CN 104415027 A CN104415027 A CN 104415027A
- Authority
- CN
- China
- Prior art keywords
- garlicin
- bulbus allii
- medicine
- group
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 69
- 230000000968 intestinal effect Effects 0.000 title abstract description 53
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 title abstract description 19
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 title abstract description 5
- 235000010081 allicin Nutrition 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 44
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 235000013305 food Nutrition 0.000 claims abstract description 26
- 230000036039 immunity Effects 0.000 claims abstract description 19
- 206010020772 Hypertension Diseases 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 17
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 16
- 208000008589 Obesity Diseases 0.000 claims abstract description 14
- 235000020824 obesity Nutrition 0.000 claims abstract description 14
- 230000000813 microbial effect Effects 0.000 claims description 51
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 44
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 24
- 230000001105 regulatory effect Effects 0.000 claims description 18
- 230000002708 enhancing effect Effects 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 230000003203 everyday effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 229920001688 coating polymer Polymers 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 239000006041 probiotic Substances 0.000 abstract description 12
- 235000018291 probiotics Nutrition 0.000 abstract description 12
- 241000192031 Ruminococcus Species 0.000 abstract description 11
- 241000186000 Bifidobacterium Species 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 4
- 210000000936 intestine Anatomy 0.000 abstract 2
- 230000037396 body weight Effects 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 35
- 239000000047 product Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 239000000463 material Substances 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 239000013641 positive control Substances 0.000 description 19
- 241000700159 Rattus Species 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 240000002234 Allium sativum Species 0.000 description 16
- 235000004611 garlic Nutrition 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000000529 probiotic effect Effects 0.000 description 11
- 241000186016 Bifidobacterium bifidum Species 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 210000001541 thymus gland Anatomy 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 108010006464 Hemolysin Proteins Proteins 0.000 description 8
- 244000223014 Syzygium aromaticum Species 0.000 description 8
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000003228 hemolysin Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 241000588807 Bordetella Species 0.000 description 6
- 241000605902 Butyrivibrio Species 0.000 description 6
- 241000186394 Eubacterium Species 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 241000194036 Lactococcus Species 0.000 description 6
- 230000035487 diastolic blood pressure Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005180 public health Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000976 ink Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UBAXRAHSPKWNCX-UHFFFAOYSA-N diallyl trisulfide Chemical compound C=CCSSSCC=C UBAXRAHSPKWNCX-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000003516 hyperlipidaemic effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000013370 mutualism Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241001300301 uncultured bacterium Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses an application of allicin in adjusting animal intestinal flora, an application of allicin in preparation of medicines, the medicines, foods, applications of the medicines and the foods in adjusting the animal intestinal flora, and a method for adjusting the animal intestinal flora. Inventors discover that by adopting allicin, numbers of probiotics such as bifidobacterium, ruminococcus and the like in animal intestines can be significantly improved, so that the animal intestinal flora can be significantly adjusted, and thus the immunity of the animal intestines can be enhanced by virtue of the action of the intestinal flora, and diseases such as obesity, diabetes, hypertension, hyperlipidemia or tumors and the like can be prevented or treated.
Description
Technical field
The present invention relates to the novelty teabag of garlicin, particularly, relate to garlicin and regulating the purposes in microbial population of animal intestinal tract.More specifically, the present invention relates to garlicin and regulating the purposes in microbial population of animal intestinal tract, the purposes in medicine prepared by garlicin, medicine and food and regulating the purposes in microbial population of animal intestinal tract, and regulates the method for microbial population of animal intestinal tract.
Background technology
A large amount of symbiosis floras is there is in normal human, these antibacterial major parts colonize in the intestinal of people, and quantity, more than 1,000 trillion, is equivalent to 10 times of human body cell sum, its microbial gene quantity is about 3,000,000, is approximately more than 100 times of human genome gene dosage.The gene of magnanimity like this can help microorganism to adapt to changeable environment, defines the mutualism relation inseparable with human body simultaneously.Completing of the Human Genome Project, make the mankind more deep to the understanding of oneself, but the genome understanding the mankind can not hold the health of the mankind completely, the micropopulation of forever settling down in human body intestinal canal is extremely far-reaching on the impact of human health, little of digestive tract environment, digestive problems, large to fat or thin problem, hypertension, diabetes, hyperlipidemia, cancer etc., the life and health of the mankind is closely bound up with them, and therefore human body intestinal canal microbial genome is also described as the second cover genome of the mankind.
At present, research confirms that the various diseases of human body is as all closely related with intestinal microbial population in diabetes, hypertension, hyperlipidemia, cancer etc.Intestinal microbial population fermentation polysaccharides metabolite mainly contains short key fatty acid (acetic acid, propanoic acid, butanoic acid etc.), gas (hydrogen, carbon dioxide, hydrogen sulfide and methane) and ammonia, and wherein hydrogen and carbon dioxide are the main components of gas in colon.The in vitro study of people's intestinal shows, butanoic acid can promote intestinal mucosa reparation and functional rehabilitation thereof, and the formation of inflammation-inhibiting cytokine, and the secretion of the tumor necrosis factor of intestinal epithelial cell can be reduced, play antiinflammatory and antitumor action.In addition, separately studies have reported that the change of Bacteroides and (or) Clostridia population in intestinal microbial population and the appearance of antibacterial Uncultured bacterium clonenbw1009b01c1, the hypertensive generation of Kazak ethnic population and development may be affected.Different intestinal microbial population spectrums can be caused a disease, can also diseases prevention.
But, regulate the research of microbial population of animal intestinal tract aspect still to need deeply at present.
Summary of the invention
The present invention is intended at least to solve one of technical problem existed in prior art.For this reason, one object of the present invention is to propose a kind of means that effectively can regulate microbial population of animal intestinal tract.
Inventor studies discovery, garlicin can significantly improve the quantity of the probiotic bacteria such as bacillus bifidus, Ruminococcus in intestinal, regulate the intestinal microbial population of animal, and then play the effects such as enhancing immunity, fat-reducing, blood sugar lowering, blood pressure lowering, blood fat reducing, antitumor by the effect of intestinal microbial population, and without any side effect, can long-term taking.Known, garlicin (allicin), chemistry diallyl trisulfide by name, it is the principle active component of Bulbus Allii, be slightly soluble in water, be dissolved in the organic solvents such as ethanol, benzene, ether, present stage also has no the research of garlicin in regulating intestinal canal flora and report.
Thus, according to an aspect of the present invention, the invention provides garlicin and regulate the purposes in microbial population of animal intestinal tract.According to embodiments of the invention, garlicin can significantly improve the quantity of the probiotic bacteria such as bacillus bifidus, Ruminococcus in animal intestinal, thus significantly can regulate the intestinal microbial population of animal, and then played the effects such as enhancing immunity, fat-reducing, blood sugar lowering, blood pressure lowering, blood fat reducing, antitumor by the effect of intestinal microbial population.Thus, can effectively regulate its intestinal microbial population to animals administer garlicin, thus strengthen its immunity, the diseases such as prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
It should be noted that, the animal species of term " animal " indication in expression way " garlicin is regulating the purposes in microbial population of animal intestinal tract " used in this article is not particularly limited.According to embodiments of the invention, this animal can be any animal with intestinal organ, and preferred mammal, more preferably rat, mice, people, optimum is chosen.In addition, used in this article expression way " prevention or treatment " mainly refers to the diseases such as prevention or auxiliary treatment obesity, diabetes, hypertension, hyperlipidemia and tumor.
According to embodiments of the invention, take garlicin without any side effect, thus the dosage of garlicin is not particularly limited, as long as can improve by the quantity of the probiotic bacteria such as bacillus bifidus, Ruminococcus in administration animal intestinal and the intestinal microbial population effectively regulating animal.According to concrete examples more of the present invention, described garlicin is carried out administration with the dosage of 0.3-1.0mg/kg to described animal.According to other embodiments of the present invention, described garlicin is carried out administration with the dosage of 0.5mg/kg to described animal.Thus, increased obviously by the quantity of the probiotic bacteria such as bacillus bifidus, Ruminococcus in administration animal intestinal, namely garlicin regulates the Be very effective of microbial population of animal intestinal tract.
According to embodiments of the invention, namely the source of garlicin provides form to be not particularly limited, such as, directly by commercial acquisition, also can provide with the garlic products being rich in garlicin.According to some embodiments of the present invention, described garlicin provides with at least one form being selected from Bulbus Allii juice, Bulbus Allii powder, black Bulbus Allii juice and black Bulbus Allii powder.
Further, according to another aspect of the invention, regulating the effect in microbial population of animal intestinal tract based on above-mentioned garlicin, present invention also offers garlicin and preparing the purposes in medicine, described medicine is for regulating microbial population of animal intestinal tract.
Said medicine can be used in regulating microbial population of animal intestinal tract, and then can play the effects such as enhancing immunity, fat-reducing, blood sugar lowering, blood pressure lowering, blood fat reducing, antitumor by the effect of intestinal microbial population.Thus, according to embodiments of the invention, described medicine is used for enhancing immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
According to embodiments of the invention, every day is to the garlicin of the preferred 0.5mg/kg of described animals administer 0.3-1.0mg/kg.Thus, can significantly improve by the quantity of the probiotic bacteria such as bacillus bifidus, Ruminococcus in administration animal intestinal, regulate the intestinal microbial population of animal, and then effectively prevent or treat the diseases such as obesity, diabetes, hypertension, hyperlipidemia or tumor by the effect of intestinal microbial population.
As previously mentioned, namely the source of garlicin provides form to be not particularly limited, and directly by commercial acquisition, also can provide with the garlic products being rich in garlicin.According to some embodiments of the present invention, described garlicin provides with at least one form being selected from Bulbus Allii juice, Bulbus Allii powder, black Bulbus Allii juice and black Bulbus Allii powder.
According to a further aspect in the invention, present invention also offers a kind of medicine.According to embodiments of the invention, this pharmaceutical pack contains: garlicin; And pharmaceutically acceptable excipient.Inventor is surprised to find, medicine of the present invention can significantly improve by the quantity of the probiotic bacteria such as bacillus bifidus, Ruminococcus in administration animal intestinal, regulate the intestinal microbial population of animal, and then effectively prevent or treat the diseases such as obesity, diabetes, hypertension, hyperlipidemia or tumor by the effect of intestinal microbial population.
As previously mentioned, namely the source of the garlicin comprised in medicine of the present invention provides form to be not particularly limited, and directly by commercial acquisition, also can provide with the garlic products being rich in garlicin.According to some embodiments of the present invention, described garlicin provides with at least one form being selected from Bulbus Allii juice, Bulbus Allii powder, black Bulbus Allii juice and black Bulbus Allii powder.
According to embodiments of the invention, the kind of excipient is not particularly limited, as long as medicine can be made to form the dosage form of easily carrying out administration.According to concrete examples more of the present invention, described excipient is at least one being selected from binding agent, filler, film-coating polymer, plasticizer, fluidizer, disintegrating agent and lubricant.
According to embodiments of the invention, the dosage form of medicine of the present invention is not particularly limited, as long as can be convenient to carry out administration.According to concrete examples more of the present invention, described medicine is in the form of at least one being selected from capsule, pill, tablet, granule, liquid oral, oral pastes, aerosol and spray.According to preferred embodiments more of the present invention, described medicine is the form of capsule.Thus, be easy to carry out administration.
According to embodiments of the invention, the dosage of medicine of the present invention is not particularly limited, and in practical application, can select flexibly according to the health status of administration object.According to some embodiments of the present invention, the dosage of described medicine is 0.3-1.0mg garlicin/kg, preferred 0.5mg garlicin/kg.Thus, significantly increased by the quantity of the probiotic bacteria such as bacillus bifidus, Ruminococcus in administration animal intestinal, regulate the Be very effective of microbial population of animal intestinal tract.
According to embodiments of the invention, described medicine is for regulating microbial population of animal intestinal tract.And then, the effects such as enhancing immunity, fat-reducing, blood sugar lowering, blood pressure lowering, blood fat reducing, antitumor can be played by the effect of intestinal microbial population.Thus, according to other embodiments of the present invention, described medicine is used for enhancing immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
In accordance with a further aspect of the present invention, present invention also offers a kind of food.According to embodiments of the invention, this food product packets contains: garlicin; And acceptable additive in bromatology.According to embodiments of the invention, food of the present invention can significantly improve by the quantity of the probiotic bacteria such as bacillus bifidus, Ruminococcus in administration animal intestinal, the intestinal microbial population of effective adjustment animal, and then effectively prevent or treat the diseases such as obesity, diabetes, hypertension, hyperlipidemia or tumor by the effect of intestinal microbial population.
It should be noted that, term " food " used in this article should make broad understanding, its can be any can by the form eaten, namely except the food form of routine, food of the present invention can also be health product, beverage etc.
According to embodiments of the invention, the form that provides of garlicin is not particularly limited, and directly by commercial acquisition, also can provide with the garlic products being rich in garlicin.According to some embodiments of the present invention, described garlicin provides with at least one form being selected from Bulbus Allii juice, Bulbus Allii powder, black Bulbus Allii juice and black Bulbus Allii powder.
According to a further aspect in the invention, present invention also offers foregoing medicine or food, regulate the purposes in microbial population of animal intestinal tract.Inventor finds, to the foregoing medicine of the present invention of animals administer or food, can significantly improve by the quantity of the probiotic bacteria such as bacillus bifidus, Ruminococcus in administration animal intestinal, the intestinal microbial population of effective adjustment animal, and then effectively prevent or treat the diseases such as obesity, diabetes, hypertension, hyperlipidemia or tumor by the effect of intestinal microbial population.
It should be noted that, term " administration " used in this article should make broad understanding, except the drug administration of routine, to feed for can be understood as during food or to provide this food animal.
According to another aspect of the invention, present invention also offers a kind of method regulating microbial population of animal intestinal tract.According to embodiments of the invention, the method is to described animals administer garlicin, foregoing medicine or food.According to embodiments of the invention, utilize method of the present invention can significantly improve by the quantity of the probiotic bacteria such as bacillus bifidus, Ruminococcus in administration animal intestinal, the intestinal microbial population of effective adjustment animal, and then effectively prevent or treat the diseases such as obesity, diabetes, hypertension, hyperlipidemia or tumor by the effect of intestinal microbial population.
In addition, according to embodiments of the invention, garlicin and comprise food of the present invention or the medicine of garlicin, the effect strengthening animal immunizing power is better than the action effect of the Radix Astragali of single component, oligofructose, oligochitosan or yeast dextran.
Also it should be noted that, the novelty teabag of garlicin of the present invention---regulating the purposes in microbial population of animal intestinal tract, the present inventor just surprisingly finds through arduous creative work and a large amount of experimental works just.
Additional aspect of the present invention and advantage will part provide in the following description, and part will become obvious from the following description, or be recognized by practice of the present invention.
Detailed description of the invention
Embodiments of the invention are described below in detail.Embodiment described below is exemplary, only for explaining the present invention, and can not be interpreted as limitation of the present invention.Unreceipted concrete technology or condition in embodiment, (such as show with reference to J. Pehanorm Brooker etc. according to the technology described by the document in this area or condition, " Molecular Cloning: A Laboratory guide " that Huang Peitang etc. translate, the third edition, Science Press) or carry out according to product description.Agents useful for same or the unreceipted production firm person of instrument, be and by the conventional products of commercial acquisition, such as, can be able to purchase from Illumina company.
Garlicin of the present invention, Bulbus Allii, Bulbus Allii juice, Bulbus Allii powder, black Bulbus Allii, black Bulbus Allii juice, black Bulbus Allii powder all can be buied from market, or prepare according to existing routine techniques extraction on demand, here do not tire out one by one and state.Describe the preparation method of capsulae allitridi, Bulbus Allii juice, Bulbus Allii powder, black Bulbus Allii juice, black Bulbus Allii powder below in embodiment 1-5, but be not limitation of the present invention.
Embodiment 1: the preparation of capsulae allitridi
Raw material: garlicin 8 parts, granular starch 6 parts
Preparation method: take garlicin 8 parts, granular starch 6 parts, research of super-pine crush equipment processing is adopted to pulverize, the grain diameter of pulverized garlicin, granular starch is made to be the fine powder of 100 microns, homogenizing becomes mixing fine powders, content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
Embodiment 2: the preparation of Bulbus Allii juice
Raw material: fresh garlic
Preparation method: select fresh garlic of uniform size, peeling, cleans the garlic clove of peeling, and clothing film is gone to the greatest extent, with rustless steel crusher in crushing 5min.To squeeze the juice 10min with juice extractor (8000rpm), then to filter after 5min through centrifuge with 60 order screen cloths and namely obtain Bulbus Allii juice.
Embodiment 3: the preparation of Bulbus Allii powder
Raw material: fresh garlic
Preparation method: select fresh garlic of uniform size, peeling, cleans the garlic clove of peeling, and clothing film is gone to the greatest extent, and garlic clove is placed in low-temperature drying equipment, and constant temperature 5-6 hour under 60 DEG C of conditions, to water content lower than 5%; By dried garlic clove screening and removing impurities, pulverize until become powder with pulverizer, namely obtain Bulbus Allii powder with 80-100 mesh sieve.
Embodiment 4: the preparation of black Bulbus Allii juice
Raw material: fresh black Bulbus Allii
Preparation method: select fresh black Bulbus Allii of uniform size, peeling, cleans the garlic clove of peeling, and clothing film is gone to the greatest extent, with rustless steel crusher in crushing 5min.To squeeze the juice 10min with juice extractor (8000rpm), then to filter after 5min through centrifuge with 60 order screen cloths and namely obtain black Bulbus Allii juice.
Embodiment 5: the preparation of black Bulbus Allii powder
Raw material: fresh black Bulbus Allii
Preparation method: select fresh black Bulbus Allii of uniform size, peeling, cleans the garlic clove of peeling, and clothing film is gone to the greatest extent, and garlic clove is placed in low-temperature drying equipment, and constant temperature 5-6 hour under 60 DEG C of conditions, to water content lower than 5%; By dried garlic clove screening and removing impurities, pulverize until become powder with pulverizer, namely obtain black Bulbus Allii powder with 80-100 mesh sieve.
Then, with the capsulae allitridi prepared in embodiment 1-5, Bulbus Allii juice, Bulbus Allii powder, black Bulbus Allii juice and black Bulbus Allii powder, following experiment is carried out:
Embodiment 6: garlicin food of the present invention regulates the research of human body intestinal canal flora impact
1. the grouping of test-meal experiment
The regulating intestinal canal flora function human experiment experimental evaluation way of embodiment 1-5 products obtained therefrom according to Ministry of Public Health " health food inspection and assessment technical specification (2003) " is evaluated.
Here is the grouping of test-meal experiment:
Table 1 test-meal experiment grouped table
2. human experiment experimental technique
Experimenter is divided at random 6 groups, often organizes 10 people, grouping situation is as follows: group 1 is normal population, and group 2 is type ii diabetes patient, and group 3 is hyperlipemic patients, and group 4 is tumor patient, and group 5 is hyperpietic, group 6 is obese patient.
Before experimenter's test-meal, all asepticly take experimenter's feces, 16S rDNA checks order inspection intestinal microbial population, as the reference of background level.
By the grouping situation of table 1, group 1 takes capsulae allitridi, group 2 takes Bulbus Allii juice, group 3 takes Bulbus Allii powder, group 4 takes black Bulbus Allii juice, group 5 takes black Bulbus Allii powder, group 6 takes capsulae allitridi, after 4 weeks, take experimenter's feces, 16S rDNA checks order and checks intestinal microbial population, contrast with background level, contrast the multiple that its relative abundance increases.
3. intestinal microbial population detection method
First fecal sample carries out DNA extraction, V3 ~ V5 region of pcr amplification 16S rDNA, then with 454 platform order-checkings, and order-checking direction V5->V3.Average 7795 tag of each sample initial data, read long about 400bp.The final tag number average out to 3235 for analyzing, reads long about 265bp.
16S analyzes main employing mothur software (http://www.mothur.org/wiki/Mothur_manual)
Comprise Quality Control, OTU cluster, the analyses such as annotation, and on the basis completing data species taxonomy, analyze the relative abundance of each species.
4. experimental result
The sequencing data abundance contrast (improving multiple compared with the background level before test-meal) of each Pseudomonas of table 2 people intestinal microbial population
Experimental result shows, before test-meal, after test-meal, the abundance of the profitable strain of each group experimenter all has growth in various degree: organize the bacillus faecalis genus of dwelling of 1 normal population, Coprecoccus, Lactobacillus obtain growth (P < 0.05), Eubacterium, Luo Sibairui Bordetella, Bifidobacterium, Butyrivibrio, Lactococcus all significantly increase (P < 0.01); Organize the Luo Sibairui Bordetella of 2 diabeticss, Bifidobacterium, Butyrivibrio, Lactococcus obtain growth (P < 0.05), bacillus faecalis genus of dwelling, Coprecoccus, Lactobacillus, Eubacterium obtain remarkable growth (P < 0.01); Organize the Eubacterium of 3 hyperlipemic patients, Coprecoccus, Bifidobacterium obtain growth (P < 0.05), dwell bacillus faecalis genus, Lactobacillus, Luo Sibairui Bordetella, Butyrivibrio, Lactococcus all significantly increase (P < 0.01); Organize the Eubacterium of 4 hyperpietics, Coprecoccus, bacillus faecalis of dwelling genus, Luo Sibairui Bordetella, Butyrivibrio, Lactococcus obtain growth (P < 0.05), Bifidobacterium, Lactobacillus all significantly increase (P < 0.01); Organize the Eubacterium of 5 tumor patients, Coprecoccus, bacillus faecalis of dwelling genus, Luo Sibairui Bordetella, Bifidobacterium, Lactococcus obtain growth (P < 0.05), Butyrivibrio, Lactobacillus all significantly increase (P < 0.01); Bacillus faecalis genus of dwelling, the Bifidobacterium of organizing 6 obese patients obtain growth (P < 0.05), and Eubacterium, Coprecoccus, Luo Sibairui Bordetella, Lactococcus, Butyrivibrio, Lactobacillus all obtain remarkable growth (P < 0.01).Thus, the Be very effective of garlicin product regulating intestinal canal flora of the present invention is shown.
The present invention is tested by intestinal microbial population and discloses garlicin to have growth promoting effects effect to the probiotic bacteria in intestinal first.
Embodiment 7: the hypoglycemic zoopery of garlicin
According to the auxiliary hyperglycemic function zoopery evaluation method of Ministry of Public Health " health food inspection and assessment technical specification (2003) ", embodiment 1 gained capsulae allitridi is evaluated, specific as follows:
1, test method: get male SD rat 50, prepares low dose of streptozotocin according to standard method and causes diabetes rat model, be divided into 5 groups at random after three days according to rat blood sugar value, often organizes 10.Each group of continuous gastric infusion 8 days, every day 1 time, dosage is 0.5mg garlicin/kg, and last two hours after administration gets blood, measures blood glucose value.
2, subjects: tested SD rat is divided into 5 groups at random, often organizes 10, tested SD rat primary diet control and movable constant, and group 1 takes capsulae allitridi, group 2 takes Bulbus Allii juice, group 3 takes Bulbus Allii powder, group 4 takes black Bulbus Allii juice, group 5 takes black Bulbus Allii powder.
3, experimental result
The hypoglycemic result of different experiments group is as shown in table 3.
Table 3 different experiments group blood sugar decreasing effect compares
Note: (1) compares with blank group
*p<0.01; (2) compare with blank group
△p<0.05
The animal test results of table 3 shows, garlicin product of the present invention all has decline effect to the hyperglycemia of experimental diabetes in rats, and display garlicin product has hypoglycemic function, has significant auxiliary therapeutic action to diabetes.
Embodiment 8: the zoopery of garlicin blood fat reducing
According to the auxiliary lipid-lowering function zoopery evaluation method of Ministry of Public Health " health food inspection and assessment technical specification (2003) ", embodiment 1-5 gained garlicin Related product is evaluated, specific as follows:
1, test material and method:
Wistar male rat 30, body weight 200 ± 20g, is provided by Wuhan University's Experimental Animal Center.Bring out rat hyperlipidemia pathological model formula (high lipid food): in normal feedstuff, add 1% cholesterol, 10% egg yolk, 10% Adeps Sus domestica, dry in bulk.
The preparation method of Hyperlipemia model rat: Wistar male rat is divided at random 5 groups (often organizing 10), i.e. hyperlipemia rat (hyperlipidemia model control group), to feed high lipid food (based on high lipid food formula feedstuff 93.8%, cholesterol 1.0%, Adeps Sus domestica 5.0%, cholate 0.2%), do not give tested material;
Medication:
Tested Hyperlipemia model rat is divided into 5 groups at random, often organize 10, the former diet control of tested Hyperlipemia model rat and movable constant, group 1 takes capsulae allitridi, group 2 takes Bulbus Allii juice, group 3 takes Bulbus Allii powder, group 4 takes black Bulbus Allii juice, group 5 takes black Bulbus Allii powder, and dosage is 0.5mg garlicin/kg.
All animals are all raised 20 days under equivalent environment.After last gives the 4h of each tested material, get hematometry serum total cholesterol (TC mmol/L, iron chloride development process), serum triacylglycerol (TG mmol/L, acetylacetone method), HDL-C (HDL-C mmol/L, phosphotungstic acid method).
2, experimental result
The content of each group of rat blood serum total TG, TC and HDL-C is in table 4.
The effectiveness comparison of TC, TG, HDL-C falls in table 4 different experiments group
Note: (1)
*represent P<0.05; (2)
*represent P<0.01
From the above results: compared with before test-meal, take the rat of the garlicin product that embodiment of the present invention 1-5 prepares, test-meal after 30 days Rat Cholesterol, triglyceride comparatively all have obvious reduction before test-meal, high density lipoprotein comparatively has obvious rising before test-meal, shows that garlicin product of the present invention has significant auxiliary therapeutic action to hyperlipemia.
Embodiment 9: the human experiment experiment of garlicin reducing blood sugar and blood fat
According to auxiliary hyperglycemic, the hypolipemic function human experiment experimental evaluation way of Ministry of Public Health " health food inspection and assessment technical specification (2003) ", embodiment 1-5 gained garlicin product is evaluated, specific as follows:
1, human experiment and test method:
Select 50 routine type Ⅱdiabetes mellitus people, wherein male 30 people by the principle of voluntariness, women 10 people, the range of age 43-75 year, without complication such as severe cardiac Liver and kidney, contrast design after taking in before test-meal.
Experimenter is divided into 5 groups at random, often organize 10 people, experimenter's former medicine kind, diet control and activity are constant, group 1 takes capsulae allitridi, group 2 takes Bulbus Allii juice, group 3 takes Bulbus Allii powder, group 4 takes black Bulbus Allii juice, group 5 takes black Bulbus Allii powder, daily 1 time, in one after each meal, take 30 days continuously, dosage is 0.5mg garlicin/kg.
The change of monitoring patient blood pressure, defecation, body weight, and the blood glucose (with glucose oxidase method) measuring empty stomach and 2 hours after the meal; Measure blood fat (T-CHOL TC, triglyceride TG and high density lipoprotein HDL-C).
2, judgment criteria:
Effective: fundamental symptoms disappears, on an empty stomach or the blood glucose of 2 hours after the meal comparatively treat before decline and be no more than 30.0%.
Effective: fundamental symptoms obviously improves, on an empty stomach and the blood glucose of 2 hours after the meal comparatively treat before decline and be no more than 10.0%.
Invalid: fundamental symptoms is not improved, on an empty stomach and the blood glucose of 2 hours after the meal comparatively treat before decline and be less than 10.0%.
3, human experiment result:
Test-meal, after 30 days, takes the patient of each garlicin product, compared with before test-meal, and the blood pressure of patient, defecation, body weight there are no significant difference, but fasting glucose, 2h-plasma glucose all have obvious attenuating, and concrete outcome is in table 5.
Impact about on the blood fat before and after test-meal: the patient taking each group of compositions, compared with before test-meal, the cholesterol of test-meal patient after 30 days, triglyceride comparatively all have obvious reduction before test-meal, and high density lipoprotein comparatively has obvious rising before test-meal, and concrete outcome is in table 6.
As can be seen here, garlicin product of the present invention has the health care of obvious auxiliary hyperglycemic, blood fat reducing, and to the harmless effect of tested population health.
Table 5 foretastes crowd's blood glucose test results
Table 6 foretastes crowd's lipids detection result
Note: (1)
*represent P<0.05; (2)
*represent P<0.01
Embodiment 10: garlicin is in the zoopery of anti-tumor aspect
According to the adjunct antineoplastic function zoopery evaluation method of Ministry of Public Health " health food inspection and assessment technical specification (2003) ", embodiment 1-5 products obtained therefrom is evaluated, specific as follows:
1, test material and method:
BALB/c mouse (4-6 age in week, male, body weight 20-24g) 60, is seeded in the right axil of BALB/c mouse by the hepatoma cells MM45T.Li of exponential phase subcutaneous, every only inoculation 5 × 10
7individual cell, sets up Transplanted tumor model.
Medication:
Tested rat model is divided into 6 groups at random, often organize 10, former diet control and movable constant, group 1 takes capsulae allitridi, group 2 takes Bulbus Allii juice, group 3 takes Bulbus Allii powder, group 4 takes black Bulbus Allii juice, group 5 takes black Bulbus Allii powder, group 6 takes normal saline, successive administration 30 days, dosage is 0.5mg garlicin/kg.Observe ordinary circumstance and tumor size change before and after mice treatment.
Become after tumor and measure the most major diameter (a) of 1 tumor and most minor axis (b) with the every 2d of slide gauge, obtain tumor body approximate volumes (TV: volume) by formula TV=a × b2/2.Evaluate medicine tumor-inhibiting action by the following method: put to death animal in the 2d of last administration and take tumor weight, and be calculated as follows medicine tumour inhibiting rate (IR):
The average tumor of tumor growth tumour inhibiting rate=(matched group average tumor weight-garlicin product group average tumor weight)/matched group heavy × 100%.Evaluate Antitumor Activity of Drugs effect with inhibition rate of tumor growth IR, the standard of curative effect evaluation: IR < 30 is invalid, IR >=30 are effective.
The results are shown in following table.
The effectiveness comparison of table 7 different experiments group Tumor growth inhibition
The above results shows: the rat taking the garlicin product that embodiment 1-5 prepares, compared with matched group, test-meal after 30 days medicine tumour inhibiting rate all have obvious reduction, show that garlicin product of the present invention has significant auxiliary therapeutic action to tumor.
Embodiment 11: garlicin is tested the therapeutic effect of obesity
According to following steps, Evaluation operation example 1-5 gained garlicin product is to the therapeutic effect of obesity:
1, test material and method
Study subject: through health check-up Pass Test requirement, the fat volunteer of overweight degree more than 20% 50, without Other diseases, viscera function is normal.
Method: adopt own control design, experimenter is divided into 5 groups at random, often organize 10 people, take capsulae allitridi by group 1, group 2 takes Bulbus Allii juice, group 3 takes Bulbus Allii powder, group 4 takes black Bulbus Allii juice, group 5 takes black Bulbus Allii powder, daily 1 time, in one after each meal, take 30 days continuously, dosage is 0.5mg garlicin/kg.Be consistent before diet and quantity of motion and test during test-meal.Indices in test-meal on-test and at the end of each test 1 time.
2, both effectiveness observation
1. height (cm), body weight (kg) calculate standard body weight, overweight degree is measured:
Adult's standard body weight (kg)=[height (cm)-100] × 0.9,
Overweight degree (%)=(actual measurement body weight-standard body weight)/standard body weight × 100%.
2. body fat total amount (kg) and fat percentage (%) measure: measure Determination of Total Body Fat with electrical impedance instrument.
3. waistline, hip circumference (cm) are measured: use tape measuring.
3, observed result
3.1 body weight, body fat total amount and fat percentage measure
About to the body weight before and after test-meal, body fat, take each group of patient containing garlicin product, compared with before test-meal, the body weight of test-meal patient after 30 days, body fat comparatively all have obvious reduction before test-meal, Rate of body lipid comparatively has obvious rising before test-meal, and concrete outcome is in table 8.
Body weight before and after table 8 test-meal, body fat measurement result (
n=190)
Note: (1)
*represent P<0.05; (2)
*represent P<0.01
The measurement of 3.2 waistlines, hip circumference
About to the waistline before and after test-meal, hip circumference, take the patient of each group of compositions, compared with before test-meal, the waistline of test-meal patient after 30 days, hip circumference comparatively all have obvious reduction before test-meal, and concrete outcome is in table 9.
Table 9 test-meal front and back waist, hip circumference measurement result (
n=190)
Note: (1)
*represent P<0.05; (2)
*represent P<0.01
From the above results, experimenter takes containing garlicin product after 30 days continuously, and body weight, body fat total amount, Rate of body lipid, waistline, hip circumference all significantly decline.As can be seen here, garlicin product of the present invention has obvious antiobesity action to human body, and has no untoward reaction during taking.
Embodiment 12: garlicin is tested hypertensive therapeutic effect
According to following steps, Evaluation operation example 1-5 gained garlicin product is to hypertensive therapeutic effect:
Wherein, 50 routine hyperpietics, all according to the diagnostic criteria of " new Chinese medicine clinical guidance principle (first volume) ", are diagnosed as hypertension.
1, diagnostic criteria:
Systolic pressure is equal to or higher than 160mmHg(21.3kPa), diastolic pressure is equal to or higher than 95mmHg(12.721.3kPa), both have 1 through examining, and can make a definite diagnosis.
2, Therapeutic Method:
Design with own control, experimenter is divided into 5 groups at random, often organize 10 people, according to the grouping situation of the table 1 in embodiment, make that group 1 takes capsulae allitridi, group 2 takes Bulbus Allii juice, group 3 takes Bulbus Allii powder, group 4 takes black Bulbus Allii juice, group 5 takes black Bulbus Allii powder, daily 1 time, in one after each meal, take 30 days continuously, dosage is 0.5mg garlicin/kg.Be consistent before diet and quantity of motion and test during test-meal.Indices in test-meal on-test and at the end of each test 1 time.
According to the criterion of therapeutical effect in " new Chinese medicine clinical guidance principle (first volume) ", effective: 1. diastolic pressure decline 10mmHg(1.3kPa) more than, and reach normal range; Though 2. diastolic pressure is normally not near, with decline 20mmHg(2.7kPa) or more, wherein 1 must be possessed.Effective: 1. diastolic pressure declines not as good as 10mmHg(1.3kPa), but to reach normal range; 2. diastolic pressure comparatively treats the front 10 ~ 19mmHg(1.3 ~ 2.5kPa that declines), but do not reach normal range.3. systolic pressure comparatively treats front decline 30mmHg(4kPa); Wherein 1 must be possessed.Invalid: not reach above standard.
After each group of case treatment, comparitive study the results are shown in Table 10.
Blood pressure (diastolic pressure) measurement result (mmHg) before and after table 10 test-meal
| Group | Before test-meal (mmHg) | Test-meal is (mmHg) after 30 days |
| Group 1 | 102.3±1.30 | 94.3±2.30* |
| Group 2 | 96.5±1.20 | 85.1±2.60** |
| Group 3 | 106.7±1.40 | 95.3±1.70* |
| Group 4 | 103.5±1.70 | 89.4±2.00** |
| Group 5 | 104.7±2.10 | 90.3±2.30** |
Note: (1)
*represent effectively; (2)
*represent effective
From the above results, in this test-meal test, experimenter takes garlicin product after 30 days continuously, and blood pressure all has decline in various degree.As can be seen here, garlicin product of the present invention has obvious hypotensive activity to human body, and has no untoward reaction during taking.
Embodiment 13: garlicin enhancing immunity functional experiment
According to following steps, research performation example 1 gained capsulae allitridi is on the impact of animal immunizing power:
1, test material
Laboratory animal: BALB/C1 monthly age secondary mouse, male and female half and half, body weight 20 ± 2g, is in a good state of health, and is provided, production licence number by Wuhan University Experimental Animal Center: SCXK(Hubei Province) 2008-0004.Often criticize animal random packet.
The recommended dose of embodiment 1 gained capsulae allitridi is mice 1mg/kgbw every day (body weight), recommends 0.5 times, 1 times and 2 times as low dose group (0.5mg/kgbw), middle dosage group (1mg/kgbw), high dose group (2mg/kgbw) respectively using mice.
If 4 positive controls:
Positive control 1 group is astragalus polysaccharides capsule (primary raw material: the Radix Astragali, oligomeric isomaltose, Nei Monggol Shuangqi Pharmaceutical Co., Ltd., the strong word G20040082 of state's food),
Positive control 2 groups is oligofructose oral liquid (primary raw material: oligofructose, Zhuhai Shengyuan Biotechnology Co., Ltd., the strong word G20050336 of state's food),
Positive control 3 groups is chitosan oligosaccharide capsule (primary raw material: oligochitosan, Xiamen Blue Bay Science and Technology Co., Ltd., the strong word G20110158 of state's food),
Positive control 4 groups is yeast dextran capsule (primary raw material: yeast dextran, Nanjing Potomac Beauty&Health Care Co., Ltd., the strong word G20110445 of state's food).
Other main reagent reagent is: sheep red blood cell (SRBC) (SRBC), Hank ' s liquid, guinea pig serum, prepared Chinese ink.
Wherein the compound method of Hank ' s liquid is:
(1) stock solution:
NaCl:80.00g, KCl:4.00g, Na
2hPO
412H
2o:1.52g, KH
2pO
4: 0.60g, glucose: 4.0g, 0.4% phenol red liquid: 50.00mL, two water that heats up in a steamer adds and is settled to 100mL, 115 DEG C of autoclaving 15min, stored frozen.
(2) working solution:
Add the two of 9 times of volumes to stock solution and heat up in a steamer water, 115 DEG C of autoclaving 15min.Face the 5.6%NaHCO of used time sterilizing
3solution adjust pH is to 7.2-7.4 (solution is orange red).
The preparation of normal saline: 9.00 grams of NaCl are dissolved in 991 grams pairs and heat up in a steamer in water the NaCl solution namely obtaining 0.9%.
2, test method
Administration by gavage is taked in test.Every day gavage once, blank group fills with equal volume distilled water.According to above-mentioned experimental establishment, give tested material continuously after 30 days to each group of mice, measure indices.
2.1 impacts on Mouse Weight, thymus/body weight, spleen/body weight
Mouse stomach de-neck execution afterwards in 30 days, weighs.Get Thymus and spleen, weigh Thymus and spleen weight respectively, measure thymus/body weight value, and spleen/body weight value.
2.2 on the impact of mouse antibodies cellulation (PFC)
The mensuration of antibody-producting cell, hemolytic plaque test is the method for the single antibody forming cell of a kind of vitro detection (plasma cell).
Lumbar injection 0.2mL2% (v/v) SRBC immunity every mice.Immunity is after 5 days, and getting mouse spleen, to make cell concentration be 5 × 10
6the splenocyte liquid of individual/mL.Dissolve the solution that agarose makes l%, in 48 DEG C of water bath heat preservations, mix with Hank ' the s liquid of equivalent 2 times of concentration, divide and be filled in small test tube, often pipe 0.5mL.Add 0.05mL10%SRBC and 0.01mL splenocyte suspension, mix rapidly, be poured on slide.Incubation lh in 37 DEG C of calorstats, is added in complement (guinea pig serum) in slide groove, then incubation 1.5h.Counting plaque.
2.3 impacts (mensuration of serum hemolysin) on mice hemolytic antibody nucleus formation
Lumbar injection 0.2mL2% (v/v) SRBC immunity every mice.Immunity, after 5 days, is plucked eyeball and is got blood in centrifuge tube, places 1h, 3000rpm centrifugal 5 minutes, collects serum.Serum normal saline dilution 400 times, adds the mice serum 1.0mL of dilution, the SRBC0.5mL of 10% (v/v), complement (with normal saline 1:10 dilution) 1.00mL successively.Separately establish the control tube of the not increase serum replaced with normal saline.Put 37 DEG C of water-baths and after 20 minutes, set to 0 DEG C refrigerator 30 minutes stopped reactions, centrifugal 5 minutes of 3000rpm.Get supernatant 1.0mL, measure optical density value in spectrophotometer 540nm wavelength place.
2.4 impacts on mice carbonic clearance
Every mouse tail vein injection is diluted to the prepared Chinese ink of 4 times, 0.1mL/10g body weight.Timing immediately after prepared Chinese ink injects.2.0mL0.1%Na is added to respectively within l minute, 10 minutes, getting blood 0.02mL after injection prepared Chinese ink
2cO
3in solution (i.e. 1g/L), measure optical density value in 600nm wavelength place, with Na
2cO
3solution compares.Separately get liver and spleen is weighed.The ability of mice carbonic clearance is represented with phagocytic index (α).
3, result of the test
The measurement result of 3.1 body weight, thymus/body weight, spleen/body weight
Each tested material is to Mouse Weight, thymus/body weight ratio, and the impact of spleen/body weight ratio, and measurement result is as shown in table 11,12 and 13.
The each tested material of table 11 is on the impact of Mouse Weight
As shown in Table 11, before per os gives the tested material of mice various dose, and after 30 days, basic, normal, high 3 dosage groups are compared with blank group and positive controls, body weight, all without significant difference (P>0.05), namely feeds the sample of 3 basic, normal, high dosage groups and 4 positive controls to the body weight of mice without impact to mice.
Table 12 tested material is on the impact of mouse thymus/body weight ratio
As shown in Table 12, per os gave the tested material of mice various dose after 30 days, compare with blank group, each dosage group thymus/all there were significant differences for body weight ratio (P < 0.05), namely increases all to some extent to the feed thymus/body weight ratio of sample to mice of 3 dosage groups and 4 positive controls of mice.
Table 13 tested material is on the impact of mouse spleen/body weight ratio
As shown in Table 3, per os gave the tested material of mice various dose after 30 days, compare with blank group, each dosage group spleen/all there were significant differences for body weight ratio (P < 0.05), namely increases all to some extent to the feed spleen/body weight ratio of sample to mice of 3 dosage groups and 4 positive controls of mice.
3.2 antibody-producting cells (PFC) measurement result
Shown in antibody-producting cell (PFC) testing result table 14.
Table 14 tested material is on the impact of mouse antibodies cellulation number
As shown in Table 14, per os gave the tested material of mice various dose after 30 days, compare with blank group, there were significant differences (P < 0.05) for the PFC quantity of positive control 1 group and low, middle dosage group, high dose group and 3 positive controls are described on mice PFC without impact, and positive control 1 group, low dose group, middle dosage group there is appreciable impact to mice PFC.
The measurement result of 3.3 serum hemolysins
The measurement result of serum hemolysin is as shown in Table 15.
Table 15 tested material is on the impact of mice serum hemolysin
As shown in Table 15, per os gave the tested material of mice various dose after 30 days, compared with blank group, the HC of low dose group, middle dosage group
50all there is pole significant difference (P < 0.01), the HC that positive control is 3 groups
50there were significant differences (P < 0.05), and low dose group of the present invention and middle dosage group are described, all can improve mice serum hemolysin HC significantly in pole
50, positive control 3 groups can significantly improve mice serum hemolysin HC
50, and positive control 1 group, positive control 2 groups, positive control 4 groups, high dose group are to mice serum hemolysin HC
50without impact.
3.4 mice carbonic clearance experimental results
Mice carbonic clearance experimental result is shown in table 16.
Table 16 tested material is on the impact of mice carbonic clearance
As shown in Table 16, per os gave the tested material of mice various dose after 30 days, compare with blank group, middle dosage group, the high dose group of garlicin product of the present invention have pole significant difference (P<0.01) to mouse macrophage phagocytic activity, low dose group, positive control 1 group, positive control 2 groups have significant difference (P<0.05) to mouse macrophage phagocytic activity, remaining group on mice carbonic clearance ability all without impact.This shows that garlicin product of the present invention has the effect strengthening mononuclear-macrophage phagocytic function, can strengthen the non-specific immunity of mice.
Before and after the experiment being improved immunity function by the garlicin product described in the invention described above, result shows, each batch of Mouse Weight, thymus/body weight ratio, spleen/body weight ratio are all without significant difference.In the experiment of mouse antibodies cellulation test experience, serum hemolysin determination experiment and mice carbonic clearance, its result has significant difference.Thus, can think that garlicin product of the present invention has the function and efficacy of enhancing immunity, and the effect of garlicin product of the present invention to enhancing immunity is better than the action effect of the Radix Astragali of single component, oligofructose, oligochitosan, yeast dextran.
In the description of this description, specific features, structure, material or feature that the description of reference term " embodiment ", " some embodiments ", " example ", " concrete example " or " some examples " etc. means to describe in conjunction with this embodiment or example are contained at least one embodiment of the present invention or example.In this manual, identical embodiment or example are not necessarily referred to the schematic representation of above-mentioned term.And the specific features of description, structure, material or feature can combine in an appropriate manner in any one or more embodiment or example.
Although illustrate and describe embodiments of the invention, those having ordinary skill in the art will appreciate that: can carry out multiple change, amendment, replacement and modification to these embodiments when not departing from principle of the present invention and aim, scope of the present invention is by claim and equivalents thereof.
Claims (10)
1. garlicin is regulating the purposes in microbial population of animal intestinal tract.
2. purposes according to claim 1, is characterized in that, described garlicin is carried out administration with the dosage of 0.3-1.0mg/kg to described animal,
Optionally, described garlicin is carried out administration with the dosage of 0.5mg/kg to described animal,
Optionally, described garlicin provides with at least one form being selected from Bulbus Allii juice, Bulbus Allii powder, black Bulbus Allii juice and black Bulbus Allii powder.
3. the purposes in medicine prepared by garlicin, and described medicine is for regulating microbial population of animal intestinal tract.
4. purposes according to claim 3, is characterized in that, described medicine is used for enhancing immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor,
Optionally, every day to the garlicin of the preferred 0.5mg/kg of described animals administer 0.3-1.0mg/kg,
Optionally, described garlicin provides with at least one form being selected from Bulbus Allii juice, Bulbus Allii powder, black Bulbus Allii juice and black Bulbus Allii powder.
5. a medicine, is characterized in that, comprises:
Garlicin; And
Pharmaceutically acceptable excipient.
6. medicine according to claim 5, is characterized in that, described garlicin provides with at least one form being selected from Bulbus Allii juice, Bulbus Allii powder, black Bulbus Allii juice and black Bulbus Allii powder,
Optionally, described excipient is at least one being selected from binding agent, filler, film-coating polymer, plasticizer, fluidizer, disintegrating agent and lubricant,
Optionally, described medicine in the form of at least one being selected from capsule, pill, tablet, granule, liquid oral, oral pastes, aerosol and spray,
Optionally, the dosage of described medicine is 0.3-1.0mg garlicin/kg, preferred 0.5mg garlicin/kg.
7. medicine according to claim 5, is characterized in that, described medicine for regulating microbial population of animal intestinal tract,
Optionally, described medicine is used for enhancing immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
8. a food, is characterized in that, comprises:
Garlicin; And
Acceptable additive in bromatology,
Optionally, described garlicin provides with at least one form being selected from Bulbus Allii juice, Bulbus Allii powder, black Bulbus Allii juice and black Bulbus Allii powder.
9. the medicine described in any one of claim 5-7 or food according to claim 8, regulating the purposes in microbial population of animal intestinal tract.
10. regulate a method for microbial population of animal intestinal tract, it is characterized in that,
To the medicine described in described animals administer garlicin, any one of claim 5-7 or food according to claim 8.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310390605.1A CN104415027A (en) | 2013-08-30 | 2013-08-30 | Application of allicin in adjusting animal intestinal flora |
| CN201711115022.2A CN107951876A (en) | 2013-08-30 | 2013-08-30 | Purposes of the allicin in microbial population of animal intestinal tract is adjusted |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310390605.1A CN104415027A (en) | 2013-08-30 | 2013-08-30 | Application of allicin in adjusting animal intestinal flora |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711115022.2A Division CN107951876A (en) | 2013-08-30 | 2013-08-30 | Purposes of the allicin in microbial population of animal intestinal tract is adjusted |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104415027A true CN104415027A (en) | 2015-03-18 |
Family
ID=52965853
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310390605.1A Pending CN104415027A (en) | 2013-08-30 | 2013-08-30 | Application of allicin in adjusting animal intestinal flora |
| CN201711115022.2A Pending CN107951876A (en) | 2013-08-30 | 2013-08-30 | Purposes of the allicin in microbial population of animal intestinal tract is adjusted |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711115022.2A Pending CN107951876A (en) | 2013-08-30 | 2013-08-30 | Purposes of the allicin in microbial population of animal intestinal tract is adjusted |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN104415027A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016151489A1 (en) * | 2015-03-25 | 2016-09-29 | Nestec Sa | Methods for predicting overweight risk for pets and adult percent body fat |
| CN106174260A (en) * | 2016-07-11 | 2016-12-07 | 来鑫（厦门）生物科技有限公司 | A kind of black Bulbus Allii water extract purposes in promoting intestinal emptying and containing the food of black Bulbus Allii water extract and medicine |
| CN106619696A (en) * | 2016-11-17 | 2017-05-10 | 郑州郑先医药科技有限公司 | Compound blood glucose lowering preparation |
| CN107019101A (en) * | 2017-05-04 | 2017-08-08 | 凤台硕力畜禽养殖有限公司 | The processing method of garlic in a kind of sheep feed processing |
| CN107810004A (en) * | 2016-07-08 | 2018-03-16 | 金元柱 | Poisonous insect antidotes composition |
| CN108938789A (en) * | 2018-08-13 | 2018-12-07 | 安吉艾格赛思生物科技有限公司 | A kind of more bacterium combination formulations of the adjusting intestinal microecology containing xylo-oligosaccharide |
| CN113507959A (en) * | 2019-03-05 | 2021-10-15 | 住友化学株式会社 | Composition for increasing occupancy of coprobacterium inhabitans in intestinal flora |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101040995A (en) * | 2006-03-20 | 2007-09-26 | 沈联慈 | Valid target of garlic oil and the application in preparing many kinds of medicine |
-
2013
- 2013-08-30 CN CN201310390605.1A patent/CN104415027A/en active Pending
- 2013-08-30 CN CN201711115022.2A patent/CN107951876A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101040995A (en) * | 2006-03-20 | 2007-09-26 | 沈联慈 | Valid target of garlic oil and the application in preparing many kinds of medicine |
Non-Patent Citations (4)
| Title |
|---|
| ANGELA FILOCAMO ET AL: "Effect of garlic powder on the growth of commensal bacteria from the gastrointestinal tract", 《PHYTOMEDICINE》 * |
| 宋建华: "《健康排毒》", 31 October 2007 * |
| 李雅菲等: "大蒜素临床应用的研究进展", 《成都医学院学报》 * |
| 牛志民等: "大蒜素对新生乳鼠肠道细菌移位的影响", 《中国生化药物杂志》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016151489A1 (en) * | 2015-03-25 | 2016-09-29 | Nestec Sa | Methods for predicting overweight risk for pets and adult percent body fat |
| CN107810004A (en) * | 2016-07-08 | 2018-03-16 | 金元柱 | Poisonous insect antidotes composition |
| CN106174260A (en) * | 2016-07-11 | 2016-12-07 | 来鑫（厦门）生物科技有限公司 | A kind of black Bulbus Allii water extract purposes in promoting intestinal emptying and containing the food of black Bulbus Allii water extract and medicine |
| CN106174260B (en) * | 2016-07-11 | 2021-08-17 | 育生（厦门）生物科技有限公司 | Application of black garlic water extract in promoting intestinal tract to drain air, and food and medicine containing black garlic water extract |
| CN106619696A (en) * | 2016-11-17 | 2017-05-10 | 郑州郑先医药科技有限公司 | Compound blood glucose lowering preparation |
| CN107019101A (en) * | 2017-05-04 | 2017-08-08 | 凤台硕力畜禽养殖有限公司 | The processing method of garlic in a kind of sheep feed processing |
| CN108938789A (en) * | 2018-08-13 | 2018-12-07 | 安吉艾格赛思生物科技有限公司 | A kind of more bacterium combination formulations of the adjusting intestinal microecology containing xylo-oligosaccharide |
| CN113507959A (en) * | 2019-03-05 | 2021-10-15 | 住友化学株式会社 | Composition for increasing occupancy of coprobacterium inhabitans in intestinal flora |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107951876A (en) | 2018-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104415027A (en) | Application of allicin in adjusting animal intestinal flora | |
| CN104413334A (en) | Edible composition as well as preparation method and application thereof | |
| CN104415060A (en) | Edible composition as well as preparation method and application thereof | |
| CN109789173A (en) | Nano vesicle and application thereof from bacillus bacterium | |
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| CN104739888A (en) | Eurotium cristatum powder as well as preparation method and application thereof | |
| CN104415061B (en) | Edible composition and its production and use | |
| CN106617080A (en) | Application of lentinan in preparation of healthcare food with intestinal flora regulating function | |
| CN109010616A (en) | A kind of pure plant preparation for increasing beneficial bacteria of intestinal tract, improving intestinal flora | |
| JP2022001572A (en) | Chinese medicine prescription flora capsule, manufacturing method thereof, and use of chinese medicine prescription flora capsule in manufacture of therapeutic agents for type 2 diabetes | |
| CN109718256A (en) | For improving the unbalance composition and its preparation method and application of intestinal flora | |
| CN101612159B (en) | Application of 20(S)-ginsenoside Rh2 compound in preparing anti-fatigue medicament | |
| CN104413120A (en) | Black garlic and millet biscuit and preparation method thereof | |
| CN101940696B (en) | Method for preparing Chinese medicinal compound Zengshengping | |
| CN104415214A (en) | Application of black garlic extract in adjusting animal intestinal flora | |
| CN104415215B (en) | Purposes of the black garlic powder in microbial population of animal intestinal tract is adjusted | |
| CN107002023B (en) | Use of bacteroides in the treatment or prevention of obesity related diseases | |
| CN103651847A (en) | Formula donkey milk powder with function of coordinating intestinal flora | |
| CN113425697B (en) | Preparation and preliminary pharmaceutical evaluation method of compound qi-tonifying intestine-moistening capsule | |
| CN104739814A (en) | Application of aloe-emodin in regulating animal intestinal flora | |
| CN105663650A (en) | Probiotic fermentation traditional Chinese medicine composition for treating lung cancer and preparing method thereof | |
| CN108783469A (en) | A kind of vegetable active Gly-His-Lys and preparation method thereof adjusting intestinal flora | |
| CN108245531B (en) | Composition for improving gastrointestinal tract function and preventing and treating constipation | |
| CN107048408A (en) | Prepare improves cancer patient illness, the fermentation composition of the plant enzyme of raising life quality effect and preparation method with conditioning | |
| CN103877126B (en) | Knurl lid intends the pharmaceutical usage of shelf fungus and the pharmaceutical composition for the treatment of tumour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150318 |